XML 30 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenue:      
Core companion animal health $ 107,398 $ 84,249 $ 72,354
Other vaccines, pharmaceuticals and products 22,685 20,348 17,483
Total revenue, net 130,083 104,597 89,837
Cost of revenue 76,191 60,384 54,122
Gross profit 53,892 44,213 35,715
Operating expenses:      
Selling and marketing 22,092 21,339 19,159
Research and development 2,147 1,658 1,414
General and administrative 13,120 12,659 12,231
Total operating expenses 37,359 35,656 32,804
Operating income 16,533 8,557 2,911
Interest and other expense (income), net 29 130 (39)
Income before income taxes 16,504 8,427 2,950
Income tax expense:      
Current income tax expense 407 1,581 47
Deferred income tax expense 3,932 1,327 1,304
Total income tax expense 4,339 2,908 1,351
Net income 12,165 5,519 1,599
Net income (loss) attributable to non-controlling interest 1,657 280 (1,004)
Net income attributable to Heska Corporation $ 10,508 $ 5,239 $ 2,603
Earnings Per Share [Abstract]      
Basic earnings (loss) per share attributable to Heska Corporation, in dollars per share $ 1.55 $ 0.80 $ 0.44
Diluted earnings (loss) per share attributable to Heska Corporation, in dollars per share $ 1.43 $ 0.74 $ 0.41
Weighted average outstanding shares used to compute basic earnings per share attributable to Heska Corporation 6,783 6,509 5,951
Weighted average outstanding shares used to compute diluted earnings per share attributable to Heska Corporation 7,361 7,074 6,409